Myeloperoxidase is not useful for the early assessment of patients with chest pain
2010 (English)In: Clinical Biochemistry, ISSN 0009-9120, E-ISSN 1873-2933, Vol. 43, no 3, 240-245 p.Article in journal (Refereed) Published
BACKGROUND: Myeloperoxidase (MPO) has been listed as a potentially useful risk marker in acute coronary syndrome. However, its clinical utility in patients with acute chest pain is not yet defined. DESIGN AND METHODS: MPO (Architect, Abbott Diagnostics) was measured in 120 healthy controls and 303 chest pain patients who had been admitted to the coronary care units of three Swedish hospitals. RESULTS: Chest pain patents had significantly higher median MPO levels compared to healthy controls (120.6 vs. 78. 9 pmol/L; p<0.001). However, MPO was not useful for the diagnosis of myocardial infarction (c-statistics 0.61 [95% CI 0.54-0.67]), and Cox regression analysis revealed no independent association between MPO and mortality (adjusted hazard ratio 1.3 [95% CI 0.8-2.0]) or the composite endpoint (adjusted hazard ratio 1.1 [95% CI 0.8-1.5]) after a median follow-up of 4.9 years. CONCLUSIONS: MPO provided no clinically relevant information in the present population of chest pain patients.
Place, publisher, year, edition, pages
2010. Vol. 43, no 3, 240-245 p.
Myeloperoxidase, Acute chest pain, Risk prediction, Prognosis
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-124530DOI: 10.1016/j.clinbiochem.2009.09.026ISI: 000274104000004PubMedID: 19822136OAI: oai:DiVA.org:uu-124530DiVA: diva2:317643